A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer
Authors
Keywords
-
Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2020-02-03
DOI
10.1080/14737159.2020.1724094
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Accuracy of the cobas EGFR Mutation Assay in Non–small-cell Lung Cancer Compared With Three Laboratory-developed Tests
- (2018) Haruhiko Nakamura et al. Clinical Lung Cancer
- Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study
- (2018) Patricia Marino et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Detection of EGFR Variants in Plasma
- (2018) Cleo Keppens et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer
- (2018) Keigo Kobayashi et al. OncoTargets and Therapy
- Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
- (2018) Zhijie Wang et al. Lancet Respiratory Medicine
- Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
- (2018) Yi-Long Wu et al. LUNG CANCER
- Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients
- (2018) Hangyu Zhang et al. Translational Oncology
- Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
- (2017) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
- (2017) Tony S.K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
- (2017) Yi-Long Wu et al. LUNG CANCER
- EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
- (2016) Yi-Long Wu et al. BRITISH JOURNAL OF CANCER
- EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method
- (2016) Kana Watanabe et al. Canadian Respiratory Journal
- FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
- (2016) D. Kazandjian et al. CLINICAL CANCER RESEARCH
- Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing
- (2016) Kirsten J.M. van Nimwegen et al. CLINICAL CHEMISTRY
- Detection of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma: Comparing Cobas 4800 EGFR Assay With Sanger Bidirectional Sequencing
- (2016) Nima Mesbah Ardakani et al. Clinical Lung Cancer
- EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review
- (2016) Yuri Sheikine et al. Clinical Lung Cancer
- ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study
- (2016) Martin Reck et al. Journal of Thoracic Oncology
- A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
- (2016) Karen L. Reckamp et al. Journal of Thoracic Oncology
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer
- (2016) Xin Qian et al. Oncotarget
- Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer†
- (2015) C. Lim et al. ANNALS OF ONCOLOGY
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
- (2015) Takaaki Hasegawa et al. INTERNAL MEDICINE
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer
- (2015) Yusuke Narita et al. LUNG CANCER
- EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
- (2015) Kenneth S. Thress et al. LUNG CANCER
- Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations
- (2015) Matthijs Oyaert et al. Molecular Diagnosis & Therapy
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
- (2014) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
- (2014) Jean-Yves Douillard et al. Journal of Thoracic Oncology
- Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
- (2014) Christos Chouaid et al. LUNG CANCER
- Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer
- (2014) Hideharu Kimura et al. LUNG CANCER
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
- (2012) A. Inoue et al. ANNALS OF ONCOLOGY
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
- (2012) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number
- (2011) Benjamin J. Hindson et al. ANALYTICAL CHEMISTRY
- Detection of Epithelial Growth Factor Receptor Mutations in Cerebrospinal Fluid from Patients with Lung Adenocarcinoma Suspected of Neoplastic Meningitis
- (2011) Masato Shingyoji et al. Journal of Thoracic Oncology
- Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer
- (2009) Ruth E. Board et al. Annals of the New York Academy of Sciences
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started